QCM
SMMT icon

Qsemble Capital Management’s Summit Therapeutics SMMT Stock Holding History

Qsemble Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,419
Closed -$287K – 611
2025
Q4 		$287K Sell
16,419
-879
-5% -$16.5K 0.02% 441
2025
Q3 		$357K Buy
+17,298
New +$419K 0.04% 370

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Qsemble Capital Management's SMMT Position: Q1 2026 in Review

Qsemble Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 16,419 shares — an estimated $287K sold.

Qsemble Capital Management first reported a position in SMMT in Q3 2025 and held it in 2 quarters. The position peaked at $357K in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Qsemble Capital Management reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 16,419 Summit Therapeutics shares in Q1 2026, an estimated $287K.
  • Qsemble Capital Management first reported a position in Summit Therapeutics in Q3 2025 and held it in 2 quarters.
  • Qsemble Capital Management's Summit Therapeutics position peaked at $357K in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.